Dr Roger Stupp talks about viral therapies for glioblastoma, in particular the results of a study of DNX-2401 plus Pembrolizumab. This small study showed patient benefit in about half of the patients and 12% had objective responses. A few patients did well for a long period of time. Dr Stupp gives us his thoughts on what these benefits mean to patients. I agree with him completely that although it is not a home run, we need small steps to build upon. And we need a lot more research to make sure we do not throw out good therapies as we have with Tocagen and ICT-107. I keep saying this but my Promising Pathway Act would fit nicely into this concept. Treatments like this would be approved now, your doctor would be able to prescribe them for you and we would have much more data to judge the treatments with and to optimize the combinations used. We should never throw away a treatment that resulted in some responses until we are sure it doesn't work - or until we have something better.